Search

Drug–Microbiome Interaction Risk Screening Service

"Identify and mitigate strain-driven drug metabolism risks before they compromise efficacy or safety."

?

Will my candidate strain deplete the active drug and reduce efficacy?

?

Could it reactivate detoxified metabolites (e.g., glucuronides), causing toxicity?

?

How can we transform these risks into actionable mitigation strategies?

Send us your strain genome or drug list for a risk pre-assessment.

The Pharmacomicrobiomics Blind Spot

The human gut microbiome acts as a highly active metabolic organ, capable of chemically modifying a vast array of oral and systemic drugs. Bacterial enzymes can alter the chemical structure of pharmaceutical compounds, leading to two primary adverse outcomes:

  • Reduced Efficacy: Bacteria may degrade the active pharmaceutical ingredient (API) before it reaches its target site, effectively lowering the therapeutic dose (e.g., microbial inactivation of Digoxin).
  • Increased Toxicity: Commensal or probiotic strains can reactivate detoxified drug metabolites back into their toxic forms (e.g., glucuronides), causing severe side effects such as the gastrointestinal toxicity seen with Irinotecan (CPT-11).

For developers of Live Biotherapeutic Products (LBPs) and small molecule drugs, understanding these interactions is a requisite for safety profiling. Creative Biolabs bridges this gap with a rigorous platform combining predictive genomics and analytical chemistry.

Screening Workflow: From Genome to Metabolome

Our integrated workflow moves from high-throughput in silico predictions to low-throughput, high-fidelity in vitro validation, ensuring a cost-effective and scientifically robust risk assessment.

1

Genomic Scanning

We utilize curated HMM profiles to scan the genomes of candidate strains for enzymes known to metabolize drugs (e.g., β-glucuronidases, nitroreductases, azoreductases).

2

In Vitro Incubation

Strains identified as "at-risk" are cultured anaerobically with the target drug. Controls include heat-killed cells and drug-only media to isolate metabolic activity.

3

LC-MS/HPLC Analysis

Supernatants and cell pellets are analyzed using high-resolution mass spectrometry or HPLC to quantify parent drug depletion and the formation of specific metabolites.

4

Risk Grading

Data is synthesized into a comprehensive report grading the interaction risk (Low/Medium/High) with suggested mitigation strategies or strain substitution recommendations.

Deliverables for Drug-Microbiome Interaction Analysis

  • Quantitative In Vitro Evidence: Drug depletion curves and metabolite formation data measured by HPLC/LC-MS under gut-relevant anaerobic conditions.
  • Strain-Specific Risk Profile: A comprehensive gene-to-phenotype report identifying risk enzymes (e.g., β-glucuronidase, nitroreductase).
  • Metabolite Identification: Confirmation of known metabolites and optional High-Res MS (HRMS) for novel pathway discovery.
  • Risk Grade (Low/Medium/High): Defined by % depletion, metabolite toxicity threshold, and dose-dependency.
  • Mitigation Playbook: Actionable recommendations including strain substitution, formulation strategies (e.g., delayed release), or inhibitor feasibility.

Sample Requirements for Screening Services

1. Microbial Strains

Phase 1 (In Silico): Genome sequences (FASTA/GenBank format).
Phase 2 (Wet-lab): Glycerol stocks, lyophilized powder, or active cultures (single isolates or defined consortia).

2. Test Compounds

Pure API (~10-50 mg powder preferred) or clinical formulation. Please provide solubility information and Certificate of Analysis (CoA) if available.

3. Context

Target indication, route of administration (e.g., oral vs. IV), and any known metabolites of concern (e.g., SN-38 for Irinotecan).

Start with a Sample Submission Form

Screening Methodology: In Silico to In Vitro

We bridge the gap between gene annotation and actual enzymatic activity. Presence of a gene does not guarantee function; our platform combines in silico prediction with functional phenotypic assays to provide a definitive risk assessment.

Target Enzyme Libraries (Examples)

Enzyme Class Function Drug/Clinical Relevance
β-glucuronidases (GUS) Hydrolysis of glucuronides Reactivation of Irinotecan (SN-38G → SN-38) causing diarrhea; NSAID enteropathy.
Cgr Operon (Reductases) Lactone ring reduction Inactivation of Digoxin by Eggerthella lenta, reducing cardiac efficacy.
Azoreductases Cleavage of azo bonds Activation of prodrugs like Sulfasalazine; metabolic alteration of azo dyes.
Nitroreductases Reduction of nitro groups Metabolism of Benzodiazepines (e.g., Clonazepam) and Chloramphenicol to toxic amines.
Sulfatases Hydrolysis of sulfate esters Modulation of steroid hormone half-life and potency.

Analytical Precision

HPLC-UV/Vis: Routine quantitation for drugs with strong chromophores.
LC-MS/MS (Triple Quad): High-sensitivity detection in complex fecal matrices.
High-resolution MS (HRMS): Untargeted discovery and confident characterization of novel or unexpected metabolites, supported by accurate-mass measurement and MS/MS fragmentation.

Physiological Relevance

All assays are conducted in dedicated anaerobic workstations/chambers with gut-simulating media (e.g., GAM/mGAM), with controlled oxygen tension, pH, and redox potential to better reflect intestinal conditions.

Drug-Microbiome Screening Service Packages

Basic: Risk Scan

  • ✓ Genome assembly & QC
  • ✓ HMM-based enzyme profile scan
  • ✓ Sequence-based substrate prediction
  • ✓ "Red Flag" report

Standard: Interaction Screen

  • ✓ Everything in Basic
  • ✓ Anaerobic drug incubation
  • ✓ LC-MS/HPLC quantitation (Parent drug)
  • ✓ Risk Grading & Mitigation Playbook

Advanced: Mechanistic

  • ✓ Everything in Standard
  • ✓ Metabolite ID (Untargeted HRMS)
  • ✓ Kinetic profiling (Time-course)
  • ✓ Inhibitor/Rescue studies

Published Data: In Silico Insights into Enzymatic Risk

Our screening logic is grounded in peer-reviewed pharmacomicrobiomics research, moving beyond simple gene presence to structural and functional validation.

Mapping β-glucuronidase Variability Across Metagenomes

Not all β-glucuronidase (GUS) enzymes pose the same risk. As highlighted by Elmassry et al. (2021), the "Loop 1" structure in bacterial GUS enzymes dictates substrate specificity—determining whether an enzyme will preferentially cleave a drug glucuronide (high risk) or a dietary carbohydrate (low risk).

Our Approach: We incorporate these structural insights into our in silico phase. We don't just flag the gene; we analyze the sequence to prioritize high-risk variants before moving to wet-lab validation.

"Sequence-informed prediction prioritizes the risk, but functional validation remains the final decision step."

The Role of the Gut Microbiome in Glucuronidated Drug Metabolism. (Creative Biolabs Authorized)

Fig.1 How gut microbiome affects the metabolism of glucuronidated drugs.1,3

Applications of Drug-Microbiome Interaction Screening

From early strain selection to regulatory submission, our screening platform supports critical decision-making across the drug development lifecycle.

LBP Strain Selection & Safety

Prioritize strains with low drug-metabolizing potential for co-administration scenarios, ensuring robust safety profiling.

Oncology Supportive Care

Assess risks of microbial reactivation of drug conjugates (e.g., Irinotecan) and GI toxicity liability in chemotherapy programs.

Oral Small-Molecule Development

Identify API depletion or unexpected metabolite formation driven by gut microbes during preclinical development.

DDI Risk Assessment

Compare multiple candidate strains or consortia to rank interaction potential under conditions of microbiome variability.

Formulation & Dosing Strategy

Inform release site choice, dosing windows, or strain substitution strategies to minimize adverse interaction risks.

Regulatory Documentation

Generate comprehensive evidence packages for microbiome-related safety considerations to support IND/NDA filings.

Frequently Asked Questions

Many chemotherapy drugs, such as Irinotecan, are detoxified by the liver via glucuronidation and excreted into the gut. Bacterial β-glucuronidase (GUS) enzymes can cleave this glucuronide group, reactivating the drug into its toxic form (e.g., SN-38). This reactivation causes severe, dose-limiting diarrhea and intestinal damage. Screening helps identify risk factors or select safe probiotic strains.

Yes. Our platform is versatile. Beyond GUS, we routinely screen for nitroreductase (benzodiazepines), azoreductase (sulfasalazine), and reductase activities (e.g., Digoxin inactivation), as well as untargeted metabolomics for novel compounds.

Absolutely. If a candidate strain shows high risk, we provide a "Mitigation Playbook." This may include recommending alternative strains from the same species with lower activity, proposing enzyme inhibitors, or suggesting formulation strategies (e.g., colonic release) to bypass the interaction window.

References

  1. Elmassry, Moamen M., Sunghwan Kim, and Ben Busby. "Predicting drug-metagenome interactions: variation in the microbial β-glucuronidase level in the human gut metagenomes." PLoS One 16.1 (2021): e0244876. https://doi.org/10.1371/journal.pone.0244876
  2. Chamseddine, Ali N., et al. "Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity." Pharmacology & therapeutics 199 (2019): 1-15. https://doi.org/10.1016/j.pharmthera.2019.03.002
  3. Distributed under Open Access license CC BY 4.0, without modification.
Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Creative Biolabs-Live Biotherapeutics


ISO 9001 Certified - Creative Biolabs Quality Management System.
Contact us
Solutions

Copyright © 2026 Creative Biolabs. All Rights Reserved.

Inquiry Basket